Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03111992
Title Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

multiple myeloma

Therapies

LCL161 + Spartalizumab

CJM112 + Spartalizumab

Spartalizumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU


No variant requirements are available.